Saturday 10 October 2026 Export all AZN data to Excel Powerpack

AstraZeneca PLC

AZN Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.

159.20 0.42 +0.26%

Follow AZN

Alert me

Market cap: $246.3B
P/E: 23.6×
Fwd P/E: 23.4×
Dividend yield: 2.02%
F-score: 9/9
Altman Z: 6.26
Beneish M: −2.51
Dividend safety: 54/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.00

Total sells 2.21

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	1	—	—
Sell	—	—	—	—	—	—	1	—	—	—	—	—

Insider Ownership 3.29%

Capital & Financial Ratios $m

Market Cap 246,250.00

Revenue 61,366.00

Net Income 12,586.00

Free Cash Flow 6,265.00

Net Debt 24,447.00

Current Ratio 0.89

Debt/Equity 0.59

P/E ratio 23.62

Fwd P/E 23.40

P/S ratio 4.02

P/B ratio 4.90

Past 5Y EPS Growth 6.07%

This Y EPS Growth 12.06%

Next Y EPS Growth 11.69%

Next Y revenue growth 7.55%

Next 5Y EPS Growth 11.65%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 7.09%

10-year low 10-year high

P/S against its own 10 years 25.85%

10-year low 10-year high

P/B against its own 10 years 15.95%

10-year low 10-year high

EV/Sales against its own 10 years 19.83%

10-year low 10-year high

EV/FCF against its own 10 years 70.24%

10-year low 10-year high

Dividends

Payout Ratio 0.48

Annual Dividend Rate 3.21

Annual Dividend Yield 2.02%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	3.21	2.15 1.06
2025	3.13	2.10 1.03
2024	2.97	1.97 1.00
2023	2.90	1.97 0.93
2022	2.90	1.97 0.93
2021	2.80	1.90 0.90
2020	2.80	1.90 0.90
2019	2.80	1.90 0.90
2018	2.80	1.90 0.90
2017	2.80	1.90 0.90
2016	2.80	1.90 0.90

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6,078	5,708	5,831	5,044
Receivables	13,552	14,831	16,335	15,989
Inventory	5,424	5,288	6,557	6,932
Other	—	—	—	—
	25,054	25,827	28,723	27,965

	2023	2024	2025	Q'26
Payables	22,374	22,465	25,280	22,893
ST’ Debt	5,129	2,337	3,104	5,808
Other	1,184	1,319	767	958
	30,542	27,866	30,617	31,553

Compound Annual Growth %

	10y	5y	3y
Sales	9.05%	17.15%	9.82%
Cash Flow	15.93%	24.88%	14.11%
Earnings	13.73%	26.19%	45.96%
Book Value	10.16%	25.52%	9.55%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	15,288	15,384	—	—	—
’25	13,588	14,457	15,191	15,503	58,739
’24	12,679	12,938	13,565	14,891	54,073
’23	10,879	11,416	11,492	12,024	45,811
’22	11,390	10,771	10,982	11,208	44,351
’21	7,320	8,220	9,866	12,011	37,417
’20	6,354	6,275	6,578	7,410	26,617

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3,359	2,865	—	—	—
’25	3,713	3,386	5,134	2,342	14,575
’24	2,486	3,085	3,383	2,907	11,861
’23	3,133	1,718	3,114	2,380	10,345
’22	3,232	1,248	2,930	2,398	9,808
’21	1,934	892	1,719	1,418	5,963
’20	139	1,040	1,822	1,798	4,799

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,874	(116)	—	—	—
’25	2,754	1,558	3,409	1,098	8,819
’24	1,009	2,417	2,057	1,970	7,453
’23	2,052	1,260	2,240	1,438	6,990
’22	3,254	762	1,836	2,114	7,966
’21	1,887	694	1,076	706	4,363
’20	128	239	1,307	1,576	3,250

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.97	1.61	—	—	—
’25	1.86	1.58	1.62	1.49	3.28
’24	1.40	1.24	0.92	0.96	2.25
’23	1.16	1.18	0.88	0.62	3.82
’22	0.26	0.24	1.06	0.58	2.12
’21	1.18	0.42	(1.10)	(0.22)	0.08
’20	0.60	0.58	0.50	0.78	2.44

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	51.10	53.02	65.38	70.60	72.30	92.96	105.30	123.46	120.94	122.48	Analyst estimates 2026–2028 Powerpack
	High	70.08	71.20	83.56	102.46	129.88	128.42	143.40	153.12	175.36	188.04
People
People	Employees	59,700	61,100	64,400	70,600	76,100	83,100	83,500	89,900	94,300	96,100
	Revenue/emp, $m	0.39	0.37	0.34	0.35	0.35	0.45	0.53	0.51	0.57	0.61
Income, $m
Income, $m	Revenue	23,002	22,465	22,090	24,384	26,617	37,417	44,351	45,811	54,073	58,739
	Gross margin, %	82.06	80.78	77.66	79.82	80.09	66.76	72.06	81.95	81.12	81.90
	EBT	3,552	2,227	1,993	1,548	3,916	(265)	2,501	6,899	8,691	12,402
	EBT margin, %	15.44	9.91	9.02	6.35	14.71	(0.71)	5.64	15.06	16.07	21.11
	Net income	3,552	2,227	1,993	1,548	3,916	(265)	2,501	6,899	8,691	12,402
	Depreciation	2,357	3,036	3,753	3,762	3,149	6,530	5,480	5,387	6,688	5,733
Per share, $
Per share, $	Revenue	18.18	17.74	17.43	18.74	20.29	26.39	28.65	29.57	17.44	18.95
	Earnings	2.76	2.38	1.70	1.02	2.44	0.08	2.12	3.84	2.27	3.30
	Cash flow	3.28	2.83	2.07	2.28	3.66	4.21	6.34	6.68	3.83	4.70
	Capex	(0.64)	(0.13)	0.77	(0.27)	(1.18)	(1.13)	(1.19)	(2.17)	(1.42)	(1.86)
	Free cash flow	2.64	2.70	2.84	2.02	2.48	3.08	5.15	4.51	2.40	2.84
	Book value	13.18	13.15	11.08	11.22	11.92	27.71	23.94	25.28	13.18	15.72
	Shares, m	1,265	1,266	1,267	1,301	1,312	1,418	1,548	1,549	3,100	3,100
Valuation, ×
Valuation, ×	P/E	19.94	29.73	44.68	94.08	40.64	388.33	64.79	35.44	28.74	27.86
	P/S	3.05	3.99	4.36	5.32	4.93	4.42	4.84	4.63	7.51	9.70
	P/B	4.21	5.38	6.85	8.89	8.39	4.20	5.79	5.41	9.94	11.70
	EV/Sales	3.52	4.58	4.95	5.78	5.36	5.04	5.33	5.09	7.94	10.08
	EV/FCF	24.25	30.09	30.42	53.79	43.92	43.21	29.68	33.38	57.61	67.12
Cash, $m
Cash, $m	Operating cash flow	4,145	3,578	2,618	2,969	4,799	5,963	9,808	10,345	11,861	14,575
	Capex	(805)	(161)	979	(347)	(1,549)	(1,600)	(1,842)	(3,355)	(4,408)	(5,756)
	Free cash flow	3,340	3,417	3,597	2,622	3,250	4,363	7,966	6,990	7,453	8,819
Balance, $m
Balance, $m	Working capital	(1,994)	(3,233)	(701)	(2,554)	(763)	3,650	(3,700)	(5,488)	(2,039)	(1,894)
	Total debt	16,808	17,807	19,113	17,552	19,699	29,794	28,279	27,494	28,843	27,819
	Net debt	10,879	13,225	13,175	11,298	11,565	23,313	21,787	21,416	23,135	21,988
	Shareholders’ equity	16,669	16,642	14,044	14,596	15,638	39,287	37,058	39,166	40,871	48,719
Returns, %
Returns, %	ROA	5.71	4.77	3.48	2.19	4.99	0.13	3.26	6.03	6.86	9.38
	ROIC	11.12	7.69	7.78	7.06	11.86	1.05	3.99	8.45	9.77	12.15
	ROE	19.89	18.02	14.05	9.32	21.14	0.41	8.61	15.63	17.58	22.83

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ABBV AbbVie Inc.	$481.4B	78.1×	27.8×	+10.16% (above 0%: growing)	+290.38% (above 0%: growing)	−36.24% (below 0%: shrinking)	74.74%	37.86%	Compare
MRK Merck & Co., Inc.	$351.3B	116×	53.9×	+5.07% (above 0%: growing)	n/m	+77.03% (above 0%: growing)	73.54%	(2.61%)	Compare
NVS Novartis AG	$262.0B	21.6×	20.6×	+0.78% (above 0%: growing)	−17.39% (below 0%: shrinking)	−15.53% (below 0%: shrinking)	75.19%	31.77%	Compare
AZN AstraZeneca PLC	$246.3B	23.6×	23.4×	+6.41% (above 0%: growing)	+1.90% (above 0%: growing)	−107.45% (below 0%: shrinking)	83.60%	20.57%
AMGN Amgen Inc.	$220.3B	25.6×	22.7×	+9.53% (above 0%: growing)	+65.41% (above 0%: growing)	+82.57% (above 0%: growing)	72.04%	34.95%	Compare
GILD Gilead Sciences, Inc.	$182.4B	— (loss-making)	— (loss-making)	+10.18% (above 0%: growing)	n/m	+376.81% (above 0%: growing)	79.76%	(133.21%)	Compare
PFE Pfizer Inc.	$158.6B	37.2×	12.2×	+2.60% (above 0%: growing)	n/m	+125.17% (above 0%: growing)	72.78%	20.38%	Compare
NVO Novo Nordisk A/S	$127.8B	9.4×	—	+4.47% (above 0%: growing)	−18.68% (below 0%: shrinking)	+71.57% (above 0%: growing)	78.21%	34.48%	Compare
BMY Bristol Myers Squibb Company	$121.7B	13.0×	11.2×	+5.74% (above 0%: growing)	+153.13% (above 0%: growing)	−13.16% (below 0%: shrinking)	71.28%	31.50%	Compare
Median of peers	$201.3B	25.6×	21.7×	+5.41%	+65.41%	+74.30%	74.14%	31.64%

All 21 Drug Manufacturers General stocks →

AstraZeneca PLC (AZN) key facts

Strength: AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
AstraZeneca PLC (AZN) is a Drug Manufacturers General company in the Healthcare sector, traded in the US as an ADR.
As of October 9, 2026, AZN traded at $159.20, a market capitalization of $246.3 billion.
AstraZeneca PLC pays an annual dividend of $3.21 per share, a yield of 2.02%, with a payout ratio of 48.0%.
Return on equity was 22.8% and debt-to-equity 0.59.
Its Piotroski F-score is 9 out of 9 and its Altman Z-score is 6.26 (safe zone) for fiscal 2025.